Table 1.
Course of thyroid autoantibody positivity in recipients of islet cell grafts developing Graves hyperthyroidism following discontinuation of immunosuppressive therapy
| Pretransplantation (none) |
Posttransplantation |
|||||||
|---|---|---|---|---|---|---|---|---|
| CI and MMF |
MMF continued after stopping CI |
None after stopping CI and MMF |
||||||
| TPO-Ab | TSHR-Ab | TPO-Ab | TSHR-Ab | TPO-Ab | TSHR-Ab | TPO-Ab | TSHR-Ab | |
| Graves (n = 4) | ||||||||
| M.R. | + | − | − | − | + (2) | + (2) | + | + |
| S.V. | + | − | − | − | − | − | + (14) | + (11) |
| V.G.J. | + | − | − | − | + (3) | − | + | + (8) |
| R.I. | + | − | − | − | − | − | + (8.5) | + (8.5) |
| No Graves (n = 9) | − | − | − | − | − | − | − | − |
The number in parentheses indicates the month at which thyroid antibody positivity was first detected after stopping the calcineurin inhibitor. Ab, antibody; CI, calcineurin inhibitor.